Sysmex America announces FDA clearance of XN-Series Hematology Analyzers

Oct. 25, 2012

Sysmex America, Inc., and Sysmex Corporation, Kobe, Japan, have announced the U.S. Food and Drug Administration’s clearance of the Sysmex XN-Series Hematology Analyzers. The XN-Series enables laboratories of any size to implement advanced clinical parameters, including an all-new fluorescent platelet channel for Immature Platelet Fraction (IPF) to aid in the differential diagnosis of thrombocytopenia. The scalable, series-wide compact design delivers a smaller footprint that optimizes speed and functionality and provides automation benefits across the entire XN-Series. The series includes the Sysmex XN-1000, Sysmex XN-2000, and Sysmex XN-3000. The Sysmex XN-9000, coupled with tube sorting and archiving and HbA1c automation and powered by Intelligent Automation from the Sysmex WAM, carries the Lavender Top Management capabilities introduced by Sysmex for the management of more than 90% of most labs’ lavender top tubes. The hematology analyzers are available for sale in the U.S., Canada, and Latin America.

“The FDA clearance of the Sysmex XN-Series Hematology Analyzers enables clinical laboratories to contribute to the overall efficiency and productivity of their hospitals. Advanced clinical parameters, now available to virtually any clinical laboratory regardless of throughput, have the potential to impact treatment guidelines, care pathways, and patient flow. This has broad implications for the healthcare industry, especially considering that much of a patient’s medical record is comprised of laboratory results,” says John Kershaw, President & CEO, Sysmex America, Inc. Learn more about hematology solutions from Sysmex.